Medivir to present at Investing in Oncology Forum on April 10

(Moderate)

(Very Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

04/09/2024 - 08:12 AM EDT

STOCKHOLM, April 9, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Investing in Oncology Forum on April 10, 2024.

CEO Jens Lindberg will present Medivir with focus on data from the ongoing phase 1b/2a clinical study with fostroxacitabine bralpamide (fostrox) and how these data enable an acceleration of fostrox's development program.

Investing in Oncology Forum – hosted by Cord Communications and focusing on what difference Swedish commercial drug development can make in creating the cancer therapies of tomorrow.

The presentation will be available on Medivir's website www.medivir.com after the meeting.

For additional information, please contact

Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com

Medivir in brief

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/medivir/r/medivir-to-present-at-investing-in-oncology-forum-on-april-10,c3958701

The following files are available for download:

https://mb.cision.com/Main/652/3958701/2719863.pdf

Press release (PDF)

View original content:https://www.prnewswire.com/news-releases/medivir-to-present-at-investing-in-oncology-forum-on-april-10-302111731.html